Risperidone-d4

Risperidone-d4 is the deuterium labeled Risperidone. Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively.

Product Specifications

CAS Number

[1020719-76-9]

Product Name Alternative

R 64 766-d4

UNSPSC

12352005

Hazard Statement

H301

Target

5-HT Receptor; Dopamine Receptor; P-glycoprotein

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Field of Research

Neurological Disease

Purity

99.40

Solubility

DMSO : 10 mg/mL (ultrasonic; warming)

Smiles

FC1=CC=C(C(C2CCN(C([2H])([2H])C([2H])([2H])C3=C(C)N=C(CCCC4)N4C3=O)CC2)=NO5)C5=C1

Molecular Formula

C23H23D4FN4O2

Molecular Weight

414.51

Precautions

H301

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Nyberg S, et al. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl) . 1993;110 (3) :265-72.; Zhu HJ, et al. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology. 2007 Apr;32 (4) :757-64.; Chen ML, et al. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-α-directed cell apoptosis in neutrophils. Int Immunopharmacol. 2012 Jan;12 (1) :197-204.; Bardgett ME, et al. Adult rats treated with risperidone during development are hyperactive. Exp Clin Psychopharmacol. 2013 Jun;21 (3) :259-67.